Enable Accessibility Enable Accessibility

Our Commitment to the Patient

Patient-Banner

Why It Matters

Our purpose of Better health for people, brighter future for the world has taken on new significance during the COVID-19 pandemic. With health care systems stressed and attention focused on stemming the spread of the virus, community well-being and personal health have become inextricably linked. While pivoting to address COVID-19, Takeda remains steadfast in our commitment to prioritize patients worldwide — especially those most in need — through uninterrupted access to medicines and our world-class research and development (R&D) efforts, transformative therapies and a values-based approach to strengthening health care systems.

We believe access to health care, medicines and vaccines is a priority for people globally. By focusing our R&D efforts on four therapeutic areas — Oncology, Rare Genetic and Hematology, Neuroscience and Gastroenterology — along with other targeted investments, we can continue to push the boundaries of what’s possible in order to bring life-changing medicines and therapies to patients worldwide.

However, challenges in the global health care system persist, including uneven access to care and treatments, health inequality, lack of disease prevention, epidemics/disease elimination and pandemic preparedness. The effects of a changing climate on public health are also becoming increasingly visible, impacting the health and well-being of people around the globe. Takeda aims to address these challenges through innovative R&D, our global Access to Medicines strategy and our carbon neutrality commitment.

As a patient-first company, we partner with patients, patient organizations, caregivers and other key stakeholders to understand the burden of disease and unmet needs that our core therapeutic areas can help alleviate. These collaborations make sure we are developing medicines and that our work is in partnership with patients, not simply for patients.


Striving Toward an Accurate Diagnosis for Children

The Global Commission to End the Diagnostic Odyssey for Children with a Rare Disease (the “Global Commission”), co-chaired by Takeda, Microsoft and EURORDIS-Rare Diseases Europe, is a diverse group of patient advocates, physicians, technologists and other experts in the field working collaboratively to identify and design transformative solutions to solve the diagnostic odyssey for children with a rare disease. The partnership is committed to harnessing the power of technology by tapping into the digital health ecosystem and empowering patients to significantly shorten the often-multiyear diagnostic journey for those living with a rare disease, in order to advance its vision: a clear path to a timely, accurate diagnosis for children around the world.

Following the 2019 release of its actionable roadmap to help accelerate time to diagnosis, the Global Commission advanced two pilot projects that leverage innovative technology, including multifactorial machine learning and telegenetic consultation tools. These efforts, along with a patient empowerment and awareness pilot campaign, support Takeda’s vision to serve the needs of patients wherever they are, earn the trust of society and customers through Takeda-ism, and be recognized as best-in-class because of agility and innovation.

FY2019 Highlights At-A-Glance

Patient-AtAGlance

5,000+ R&D employees worldwide advance new treatment options

70,000+ patients from 25 underserved countries and communities received access to Takeda’s innovative medicines and vaccines, as well as other supportive health care services, through Takeda sponsored and supported clinical trials and Early Access Programs

¥492.4 billion invested in R&D

8,216 patients screened for noncommunicable diseases, including cancer, as part of our Access to Medicines efforts

948 pieces of scientific instrumentation donated to 67 research departments in
53 institutions — helping to build local research capacity in 24 countries as part of the Instrumental Access Program

200+ R&D employees participated in our Knowledge Sharing program to volunteer their skills and experience with 50 programs at 20 nonprofit partners

3,803 health care providers and community health workers trained across NCDs (cancer, diabetes, hypertension) and palliative care/patient support, including 1,417 cumulative trainees taught by Seed Educators


In This Section